These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28919755)

  • 21. TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
    Hantel C; Ozimek A; Lira R; Ragazzon B; Jäckel C; Frantsev R; Reincke M; Bertherat J; Mussack T; Beuschlein F
    Mol Cell Endocrinol; 2016 Mar; 423():87-95. PubMed ID: 26768118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo.
    Yuan W; Ernst K; Kuai R; Morin EE; Yu M; Sviridov DO; Tang J; Mei L; Li D; Ackermann R; Remaley AT; Schwendeman A
    Nanomedicine; 2023 Feb; 48():102646. PubMed ID: 36549559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.
    Yuan W; Yu B; Yu M; Kuai R; Morin EE; Wang H; Hu D; Zhang J; Moon JJ; Chen YE; Guo Y; Schwendeman A
    J Control Release; 2021 Jan; 329():361-371. PubMed ID: 33188828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo.
    Hasanovic A; Ruggiero C; Jung S; Rapa I; Signetti L; Ben Hadj M; Terzolo M; Beuschlein F; Volante M; Hantel C; Lalli E; Mus-Veteau I
    Int J Cancer; 2018 Jul; 143(1):199-211. PubMed ID: 29411361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
    Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells.
    Taylor MJ; Sanjanwala AR; Morin EE; Rowland-Fisher E; Anderson K; Schwendeman A; Rainey WE
    Endocrinology; 2016 Aug; 157(8):3122-9. PubMed ID: 27253994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
    Lee SG; Kim CH; Sung SW; Lee ES; Goh MS; Yoon HY; Kang MJ; Lee S; Choi YW
    Int J Nanomedicine; 2018; 13():3263-3278. PubMed ID: 29910614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake.
    Pilon A; Briand O; Lestavel S; Copin C; Majd Z; Fruchart JC; Castro G; Clavey V
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1074-81. PubMed ID: 10764676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas.
    Subramanian C; Zhang H; Gallagher R; Hammer G; Timmermann B; Cohen M
    World J Surg; 2014 Jun; 38(6):1343-52. PubMed ID: 24763440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
    Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
    Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
    J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models.
    Haider MS; Schreiner J; Kendl S; Kroiss M; Luxenhofer R
    Macromol Biosci; 2020 Jan; 20(1):e1900178. PubMed ID: 31596553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
    Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
    Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.